Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology - Takeaways - MDSpire

Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology

  • By

  • Xiaoqiang Wang

  • Yali Liu

  • Qiang Yang

  • Hai Zhao

  • June 30, 2026

  • 0 min

Share

  • 1

    The shift from conventional chemotherapy to precision immunotherapy marks a significant change in cancer treatment paradigms.

  • 2

    CAR-T cell therapy and bispecific antibodies have shown remarkable efficacy in hematological cancers but face challenges in solid tumors.

  • 3

    Deploying CAR-T and bispecific therapies earlier in treatment may prevent immune exhaustion and improve long-term outcomes.

  • 4

    Innovative molecular engineering aims to enhance CAR-T and bispecific therapies' effectiveness against the immunosuppressive tumor microenvironment.

  • 5

    Clinical trials like ZUMA-7 and TRANSFORM are redefining treatment strategies for large B-cell lymphoma, challenging traditional approaches.

Original Source(s)

Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology

  • by Xiaoqiang Wang, Yali Liu, Qiang Yang, Hai Zhao

  • June 30, 2026

Related Content

ESMO Breast Cancer 2026 Highlights: TRAK-ER

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the TRAK-ER trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
A glimpse into the CyberKnife robotic radiosurgery system: technical specifications and developments during thirty years

Mapping the evolving landscape of artificial intelligence in pathology: A bibliometric analysis of research trends and emerging frontiers (2009-2025)